entrez_gene	entrez_id	variant	variant_type	Disease	DOID	Drug	pubchem_id	Evidence Type	Evidence Direction	Clinical Signficance	Statement	Level	Source	stars	Include?	Variant Group
TSC2	7249	Loss-of-Function  	somatic	Bladder cancer	4007	 Everolimus	6442177	Predictive	Supports	Sensitivity	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts. 	B	23071027	3	1	TSC Loss
TSC1	7248	Loss-of-Function  	somatic	Bladder cancer	4007	 Everolimus	6442177	Predictive	Supports	Sensitivity	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts. 	B	23071027	3	1	TSC Loss
TSC1	7248	Frameshift truncation	somatic	Metastatic urothelial bladder cancer	6477	 Everolimus	6442177	Predictive	Supports	Sensitivity	A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus. 	B	22923433	3	1	TSC Loss
TSC1	7248	Frameshift truncation	somatic	NSCLC	3908	Rapamycin	5284616	Predictive	Supports	Sensitivity	Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.	C	19966866	3	1	TSC Loss
PTEN	5728	R233*	somatic	Breast Cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors. 	C	20085938	4	1	PTEN Loss-of-Function
PTEN	5728	R233*	somatic	Glioblastoma multiforme	3068	N/A	N/A	Prognostic	Supports	Poor Outcome	PTEN nonsense  , including R233*, has been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients. 	B	22479427	3	1	PTEN Loss-of-Function
BRAF	673	V600D	somatic	Melanoma	1909	Dabrafenib	44462760	Predictive	Supports	Sensitivity	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	B	23463675	5	1	Other V600's
BRAF	673	V600M	somatic	Melanoma	1909	Dabrafenib	44462760	Predictive	Supports	Sensitivity	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	B	23463675	5	1	Other V600's
BRAF	673	V600R	somatic	Melanoma	1909	Dabrafenib	44462760	Predictive	Supports	Sensitivity	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	B	23463675	5	1	Other V600's
BRAF	673	V600E/V600M	somatic	Melanoma	1909	Dabrafenib	44462760	Predictive	Supports	Sensitivity	A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.	B	23031422	3	1	Other V600's
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations are associated with FLT3-length mutations and FLT3-TKD mutations in normal karyotype AML patients	B	16076867	5	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with patients with normal karyotype and at a significantly lower incidence in patients with complex karyotype	B	16455956	5	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Complete remission rates were higher and event-free survival was longer for normal karyotype AML patients with Exon 12 NPM1  .	B	16076867	5	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	NPM1 mutations are not associated with MLL PTD mutations in normal karyotype AML patients.	B	16076867	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	MLL PTD mutations were more frequent in NPM1 wildtype patients than those with NPM1 mutations in younger (16-60) normal karyotype AML patients (p<0.001).	B	16051734	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	MLL PTD mutations were more frequent in NPM1 wildtype patients than those with NPM1 mutations in older (>60), normal karyotype AML patients.	B	19059939	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	TET2 mutations were not associated with NPM1 mutations in younger adult (<65 years) AML cases overall or in a subset of cytogenetically normal patients.	B	22430270	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutation was associated with high expression of CD33 in cells of normal karyotype patients with AML	B	15659725	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with higher myelomonocytic marker expression, lower CD34 and CD133 expression, lower myeloperoxidase, higher white blood cell count, and female sex in normal karyotype AML patients but not different with regards to age	B	16076867	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	FLT3-ITD and FLT3-TKD [D835] mutations were more frequent in younger (16-60), normal karyotype patients with NPM1 mutations than in patients wild-type for NPM1	B	16051734	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	Mutant NPM1 is associated with myelomonocytic and monocytic morphology (M4/M5 FAB subtypes) in younger (16-60) normal karyotype AML patients	B	16051734	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutation was associated with higher white blood cell and platelet counts, lower CD34 expression, higher serum HLA, higher blast count, extrameddulary involvement, lymphadenopathy and female sex in younger (16-60) normal karyotype AML patients	B	16051734	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	FLT3-ITD and FLT3-TKD mutations were more frequent in patients with NPM1 mutations than in patients wild-type for NPM1	B	16455956	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutation was associated with higher white blood cell count, lower CD34 expression, higher blast counts and female sex.	B	16455956	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	FLT3-ITD and FLT3-TKD mutations were more frequent in older (>60) patients with NPM1 mutations than in patients wild-type for NPM1	B	19059939	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with FLT3-TKD  	B	17965322	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with IDH1 R132  	B	20805365	4	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Negative	NPM1 mutations were not associated with M2 FAB subtypes	B	16076867	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with M4, M5a and M5b FAB subtypes	B	16076867	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult AML patients (median age 43)	B	17957027	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD  	B	22490330	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival, relapse-free survival and response to induction chemotherapy	B	16051734	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old	B	20026798	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	NPM1 mutation was associated with higher complete remission rates, lower cumulative incidence of relapse and higher overall survival in intermediate risk AML patients	B	24855211	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Coocurrence of FLT3-ITD mutations significantly reduced overall survival of normal karyotype AML patients	B	16455956	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3	B	21537333	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation	B	21537333	4	1	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients)	B	21067377	4	1	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	Humanized mouse knock-in model develops AML in 1/3 of animals. Transposon-induced secondary mutations in these mice reduces leukemic latency and increases the proportion of mice that get AML suggesting this mutation cooperates with others in the development of leukemia.	C	21441929	4	0	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A mutations were associated with NPM1  	B	21067377	4	0	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype)	B	21067377	4	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	NSC348884, ATRA	335974, 444795	Predictive	Supports	Sensitivity	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD	C	21719597	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	ATRA	444795	Predictive	Supports	Resistance or Non-Response	ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status	B	19965647	3	1	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	NSC348884	335974	Predictive	Supports	Sensitivity	NSC348884 induced apoptosis in OPI-AML3 cells (harbor NPM1 mutation)	C	21719597	3		NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Positive	Frequency of NPM1 mutations was not different in normal karyotype AML patients with CEPBA, NRAS or KIT mutations. 	B	16076867	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Positive	Frequency of NPM1 mutations was not different in younger (16-60), normal karyotype AML patients with CEBPA mutations than the older cohort.	B	16051734	3	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	MLL-PTD mutations were less frequent in patients with NPM1 mutations (0/207) than in patients wild-type for NPM1 (39/549).	B	16455956	3	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	NPM1 mutations were not associated with M3 FAB subtype (0/55).	B	16455956	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Positive	The frequency of NPM1 mutations was similar between younger (<60) and older (>60) patients with normal karyotype AML.	B	19047294	3	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with M5a and M5b FAB subtypes	B	16455956	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with normal karyotype in older (>60) patients	B	19059939	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved	B	19059939	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation 	B	20805365	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	B	15659725	3		NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Complete remission rates were higher and both disease-free and overall survival was longer for patients with Exon 12 NPM1  .	B	16455956	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed 	B	17965322	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants	B	19047294	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients	B	22430270	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD	B	24859829	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with NPM1 mutations and low levels of FLT3-ITD have worse overall survival and cumulative incidence of relapse than those with NPM1 mutations alone in intermediate risk AML patients	B	24855211	3	1	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	Mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.	D	15659725	3	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	ATRA	444795	Predictive	Supports	Sensitivity	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD	B	19059939	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	Daunorubicin	30323	Predictive	Supports	Sensitivity	Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.	B	22417203	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	Valproic acid	3121	Predictive	Supports	Sensitivity	For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid	B	24797300	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	NPM1 mutations were mutually exclusive of IDH2 R172 mutations (0/13 patients).	B	20368543	2	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes	B	17957027	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1 mutation was significantly associated with IDH2 (R140Q) mutations and DMNT3A mutations with adjustment for multiple comparisons.	B	22417203	2	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Resistance or Non-Response	Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15)	B	19587375	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	Intermediate risk patients with mutant NPM1 had improved overall survival with the presence either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2	B	22417203	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy	D	24927407	2	1	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Predictive	Supports	Sensitivity	CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy	D	24927407	2	1	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	NPM1-A mutation was not associated with sex or age	B	24764728	2	0	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	NPM1-A mutation was associated with higher WBC, increased association with normal karyotype and reduced CD34+ expression 	B	24764728	2	0	NPM1 exon 12
NPM1	4869	W288fs	somatic	Hematologic cancer	2531	N/A	N/A	Diagnostic	Supports	Positive	Mouse knock-in model develops myeloproliferative disease but not overt leukemia	C	23226219	2	0	NPM1 exon 12
NPM1	4869	W288fs	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	Transgenic mice expressing mutant NPM1 driven by the myeloid promotor hMRP8 develop a non-lethal myeloproliferative disorder but not overt leukemia	C	19666870	2	0	NPM1 exon 12
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	NPM1 mutation without FLT3-ITD was significantly associated with complete remission	B	18450602	3	1	NPM1 exon 12
BRAF	673	V600E	somatic	Melanoma	1909	N/A	N/A	Predictive	Does Not Support	N/A	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.	C	24576830	3	1	NF1 loss
BRAF	673	V600E	somatic	Melanoma	1909	N/A	N/A	Predictive	Supports	Resistance or Non-Response	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.	C	24576830	3	1	NF1 loss
RET	5979	C634W	somatic	Medullary thyroid carcinoma	3973	Motesanib	16097729	Predictive	Supports	Resistance or Non-Response	Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.	C	21422803	3	1	Motesanib Resistance  
RET	5979	M918T	somatic	Medullary thyroid carcinoma	3973	Motesanib	16097729	Predictive	Supports	Resistance or Non-Response	Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.	C	21422803	3	1	Motesanib Resistance  
ABL1	25	BCR-ABL T315I	somatic	CML	8552	Imatinib	5291	Predictive	Supports	Resistance or Non-Response	In patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.	B	20537386	4	1	Imatinib Resistance  
FGFR2	2263	FGFR2-MGEA5	somatic	Cholangiocarcinoma	4947	Ponatinib	24826799	Predictive	Supports	Sensitivity	In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in "anti-tumor activitiy". 	B	24550739	3	1	FGFR fusions
FGFR2	2263	FGFR2-AFF3	somatic	Breast cancer	1612	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-CASP7	somatic	Breast cancer	1612	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-CCDC6	somatic	Breast cancer	1612	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-BICC1	somatic	Cholangiocarcinoma	4947	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-SLC45A3	somatic	Prostate cancer	10283	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-KIAA1967	somatic	Squamous cell lung cancer	3907	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR2	2263	FGFR2-OFD1	somatic	Thyroid cancer	1781	Pazopanib	11525740	Predictive	Supports	Sensitivity	In cell lines harboring this fusion, pazopanib exhibited anti-neoplastic properties. 	C	23558953	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Bladder Cancer	4007	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types.	B	24550739	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Cholangiocarcinoma	4947	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types. 	B	24550739	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Glioblastoma Multiforme	3068	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types.	B	24550739	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Head and Neck Cancer	8618	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types.	B	24550739	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Oral Cancer	4947	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types.	B	24550739	3	1	FGFR fusions
FGFR3	2261	FGFR3-TACC3	somatic	Squamous Cell Lung Cancer	3907	Pazopanib, Ponatinib	11525740, 24826799	Predictive	Supports	Sensitivity	In a 50 year old male patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor "tumor shrinkage". This fusion is also shown to be reccurent in multiple other cancer types.	B	24550739	3	1	FGFR fusions
KIT	3815	D816V	somatic	Acute myeloid leukemia	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT	B	16384925	4	1	Exon 17 
KIT	3815	L576P 	somatic	Melanoma	1909	Imatinib, Nilotinib, Sorafenib	5291, 644241, 216239	Predictive	Supports	Resistance or Non-Response	The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.	C	19671763	3	1	Exon 11
KIT	3815	L576P 	somatic	NSCLC	3908	Dasatinib, Imatinib, Nilotinib	3062316, 5291, 644241	Predictive	Supports	Sensitivity	BaF3 cells harboring KIT L576P mutation are sensitive to dasantinib, nilotinib and imatinib.	C	17372901	3	1	Exon 11
KIT	3815	V654A	somatic	Gastric intestinal stromal tumor	9253	SU11248	5329102	Predictive	Supports	Sensitivity	In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.	B	16638875	3	1	Exon 11
KIT	3815	L576P 	somatic	Melanoma	1909	Dasatinib	3062316	Predictive	Supports	Sensitivity	The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.	C	19671763	3	1	Exon 11
KIT	3815	V654A	somatic	Gastric intestinal stromal tumor	9253	Imatinib	5291	Predictive	Supports	Resistance or Non-Response	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	C	16954519	3	1	Exon 11
KIT	3815	L576P 	somatic	Melanoma	1909	Imatinib	5291	Predictive	Supports	Sensitivity	In a case study, a patient with anal melanoma harboring an exon 11 KIT mutation showed marked response 4 months after imatinib treatment.	B	18421059	3	1	Exon 11
ESR1	2099	L536Q	somatic	Breast cancer	1612	Tamoxifen, Fulvestrant	2733526, 104741	Predictive	Supports	Sensitivity	5 ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	C	24185510	5	1	ESR1 Ligand-Binding Domain  
ESR1	2099	N538G	somatic	Breast cancer	1612	Tamoxifen, Fulvestrant	2733526, 104741	Predictive	Supports	Sensitivity	5 ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	C	24185510	5	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537C	somatic	Breast cancer	1612	Tamoxifen, Fulvestrant	2733526, 104741	Predictive	Supports	Sensitivity	5 ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	A	24185510	5	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537N	somatic	Breast cancer	1612	Tamoxifen, Fulvestrant	2733526, 104741	Predictive	Supports	Sensitivity	5 ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	A	24185510	5	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537S	somatic	Breast cancer	1612	Tamoxifen, Fulvestrant	2733526, 104741	Predictive	Supports	Sensitivity	5 ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	A	24185510	5	1	ESR1 Ligand-Binding Domain  
ESR1	2099	L536Q	somatic	Breast cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Surveys implicate ligand binding domain mutants in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.	C	24185512	3	1	ESR1 Ligand-Binding Domain  
ESR1	2099	N538G	somatic	Breast cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Surveys implicate ligand binding domain mutants in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.	B	24185512	3	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537C	somatic	Breast cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Surveys implicate ligand binding domain mutants in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.	B	24185512	3	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537N	somatic	Breast cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Surveys implicate ligand binding domain mutants in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.	B	24185512	3	1	ESR1 Ligand-Binding Domain  
ESR1	2099	Y537S	somatic	Breast cancer	1612	N/A	N/A	Predictive	Supports	Sensitivity	Surveys implicate ligand binding domain mutants in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.	B	24185512	3	1	ESR1 Ligand-Binding Domain  
PRKACA	5566	DNAJB1-PRKACA	somatic	Hepatocellular fibrolamellar carcinoma	5015	N/A	N/A	Diagnostic	Supports	Positive	A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from an ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.	B	24578576	4	1	DNAJB1 Fusions
DNAJB1	3337	DNAJB1-PRKACA	somatic	Hepatocellular fibrolamellar carcinoma	5015	N/A	N/A	Diagnostic	Supports	Positive	A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from an ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.	B	24578576	4	1	DNAJB1 Fusions
ALK	238	F1174L	somatic	NSCLC	3908	Crizotinib	11626560	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	C	21030459	3	1	Crizotinib Resistance  
ALK	238	EML4-ALK L1196M	somatic	NSCLC	3908	Crizotinib	20979473	Predictive	Supports	Resistance or Non-Response	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.	A	20979473	4	1	ALK Fusions, Crizotinib Resistance  
ALK	238	EML4-ALK C1156Y	somatic	NSCLC	3908	Crizotinib	20979473	Predictive	Supports	Resistance or Non-Response	In patients with non-small cell lung cancer harboring EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.	A	20979473	4	1	ALK Fusions, Crizotinib Resistance
ALK	238	EML4-ALK	somatic	NSCLC	3908	Crizotinib	20979473	Predictive	Supports	Sensitivity	In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective.	A	20979473	4	1	ALK Fusions
PML	5371	PML-RARa	somatic	APL	9119	ATRA	444795	Predictive	Supports	Sensitivity	Fusion protein undergoes proteolysis in APL cells upon ATRA treatment in cell lines.	B	8674046	5	1	
RARa	5914	PML-RARa	somatic	APL	9119	ATRA	444795	Predictive	Supports	Sensitivity	Fusion protein degradation is accelerated upon ATRA treatment at pharmalogical concentrations.	B	8674046	5	1	
CSF1R	1436	MEF2D-CSF1R	somatic	ALL	9952	Imatinib, GW-2580	5291, 11617559	Predictive	Supports	Sensitivity	Cell lines with MEF2D-CSF1R fusion show sensitivity to Tyrosine Kinase Inhibitors Imatinib and GW-2580	C	24186003	3	1	
MEF2D	4209	MEF2D-CSF1R	somatic	ALL	9952	Imatinib, GW-2580	5291, 11617559	Predictive	Supports	Sensitivity	Cell lines with MEF2D-CSF1R fusion show sensitivity to Tyrosine Kinase Inhibitors Imatinib and GW-2580	C	24186003	3	1	
SF3B1	23451	K666N	somatic	MDS	4972	N/A	N/A	Prognostic	Supports	Better Outcome	Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex.	D	21995386	3	1	
SF3B1	23451	K700E	somatic	MDS	4972	N/A	N/A	Diagnostic	Does Not Support	Negative	This mutation, along with many clustered around it, are hypothesized to be less deleterious than random mutation based on analysis using the Pfam database. 	D	21995386	3	0	
SF3B1	23451	K700E	somatic	MDS	4972	N/A	N/A	Prognostic	Supports	Better Outcome	Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex. 	D	21995386	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	WT1 mutations (69% Exon 7, 15% Exon 9) were not associated with NPM1 mutations in young (16-60) patients with cytogenetically normal AML	B	19221039	4	0	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	WT1 mutations (69% exon 7, 15% exon 9) were significantly associated with FLT3-ITD mutations in young (16-60) patients with cytogenetically normal AML.	B	19221039	4	0	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML	B	19221039	4	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	WT1 mutations (69% Exon 7, 15% Exon 9) were not associated with NPM1 mutations in young (16-60) patients with cytogenetically normal AML	B	19221039	4	0	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	WT1 mutations (69% exon 7, 15% exon 9) were significantly associated with FLT3-ITD mutations in young (16-60) patients with cytogenetically normal AML.	B	19221039	4	0	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML.	B	19221039	4	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Predictive	Supports	Resistance or Non-Response	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	No difference in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML 	B	19221039	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients	B	18559874	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML	B	19221039	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Predictive	Supports	Resistance or Non-Response	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	No difference in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML 	B	19221039	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML	B	18591546	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients	B	18559874	3	1	
WT1	7490	Exon 9	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML	B	19221039	3	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	WT1 mutations were associated with FLT3-ITD  	B	19536888	2	0	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	  in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence	B	19536888	2	1	
WT1	7490	Exon 7	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML	B	19536888	2	1	
U2AF1	7307	Q157P/R	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.	D	23029227	3	1	
U2AF1	7307	S34Y/F	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.	D	23029227	3	1	
U2AF1	7307	Q157P/R	somatic	MDS	4972	N/A	N/A	Prognostic	Supports	Poor Outcome	After adjust for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.	D	23861105	3	1	
U2AF1	7307	S34Y/F	somatic	MDS	4972	N/A	N/A	Prognostic	Supports	Poor Outcome	After adjust for age and cancer stage, presence of U2AF mutation such as S34Y/F is prognostic for poorer survival outcomes in patients with MDS.	D	23861105	3	1	
U2AF1	7307	Q157P/R	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with AML, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.	D	23029227	2	1	
U2AF1	7307	S34Y/F	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.	D	23029227	2	1	
U2AF1	7307	Q157P/R	somatic	MDS	4972	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF.	D	23029227	2	1	
U2AF1	7307	S34Y/F	somatic	MDS	4972	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1.	D	23029227	2	1	
TP53	7157	R175H	somatic	Breast cancer	1612	Doxorubicin 	31703	Predictive	Supports	Sensitivity	Breast tumor with R175H mutation are more responsive to doxorubicin than breast tumor with wild type TP53.	C	22698404	3	1	
TP53	7157	R175H	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	Breast cancer patients who harbor R175H mutation has worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	B	16489069	3	1	
TP53	7157	R248Q	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients  harboring TP53 mutation, mutations in DNA contact region such as R248 is prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	B	9569050	3	1	
TP53	7157	R248Q	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	Breast cancer patients who harbor R248Q mutation has worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	B	16489069	3	1	
TP53	7157	R248W	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53.	B	16489069	3	1	
TP53	7157	R249T	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in conserved region such as R249 is prognostic for a worse overall survival compared to those harboring wild-type TP53.	B	9569050	3	1	
TP53	7157	R249W	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in conserved region such as R249 is prognostic for a worse overall survival compared to those harboring wild-type TP53.	B	9569050	3	1	
TP53	7157	R273C	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients  harboring TP53 mutation, mutations in DNA contact region such as R273 is prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	B	9569050	3	1	
TP53	7157	R273C	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	Breast cancer patients who harbor R273C mutation has worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	B	16489069	3	1	
TP53	7157	R273H	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients  harboring TP53 mutation, mutations in DNA contact region such as R273 is prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.	B	9569050	3	1	
TP53	7157	R273H	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	Breast cancer patients who harbor R273H mutation has worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.	B	16489069	3	1	
TP53	7157	V173G/A	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In breast cancer patients harboring TP53 mutation, mutations in conserved region such as V173 is prognostic for a worse overall survival compared to those harboring wild-type TP53.	B	9569050	3	1	
RET	5979	M918T	somatic	Medullary thyroid carcinoma	3973	N/A	N/A	Diagnostic	Supports	Positive	In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.	B	18073307	5	1	
RET	5979	M918T	somatic	Medullary thyroid carcinoma	3973	N/A	N/A	Prognostic	Supports	Poor Outcome	In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of disease persistence.	B	18073307	5	0	
RET	5979	M918T	somatic	Medullary thyroid carcinoma	3973	N/A	N/A	Prognostic	Supports	Poor Outcome	Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.	B	9839497	4	1	
RET	5979	M918T	somatic	Medullary thyroid carcinoma	3973	AZD1480	16659841	Predictive	Supports	Sensitivity	The use of AZD1480 in vitro led to strong repression of tyroid cancer cell growth.	C	23056499	3	1	
MAP2K1	5604	P124S	somatic	Melanoma	1909	AZD6244	10127622	Predictive	Supports	Resistance or Non-Response	MAP2K1 P124S confers increased resistance to inhibition by AZD6244 inhibition by about 5 fold. 	C	19915144	3	1	
MAP2K1	5604	Q56P	somatic	Melanoma	1909	AZD6244	10127622	Predictive	Supports	Resistance or Non-Response	MAP2K1 Q56P confers increased resistance to inhibition by AZD6244 by 100 fold. 	C	19915144	3	1	
PIK3CA	5290	E542K	somatic	Breast cancer	1612	CH5132799	49784945	Predictive	Supports	Sensitivity	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	C	21558396	4	1	
PIK3CA	5290	E545K	somatic	Breast cancer	1612	CH5132799	49784945	Predictive	Supports	Sensitivity	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	C	21558396	4	1	
PIK3CA	5290	H1047R	somatic	Breast cancer	1612	CH5132799	49784945	Predictive	Supports	Sensitivity	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	C	21558396	4	1	
PIK3CA	5290	E542K	somatic	Colorectal cancer	9256	Regorafenib	11167602	Predictive	Does Not Support	N/A	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	B	24559322	4	1	
PIK3CA	5290	E545K	somatic	Colorectal cancer	9256	Regorafenib	11167602	Predictive	Does Not Support	N/A	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	B	24559322	4	1	
PIK3CA	5290	H1047R	somatic	Colorectal cancer	9256	Regorafenib	11167602	Predictive	Does Not Support	N/A	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	B	24559322	4	1	
PIK3CA	5290	E542K	somatic	Colorectal cancer	9256	Cetuximab, Panitumumab	56842117, NA	Predictive	Supports	Resistance or Non-Response	The presence of mutation in exon 9 (such as E542K) or exon 20 may increase resistance to drugs such as  panitumumab or cetuximab.	D	19223544	3	1	
PIK3CA	5290	E545K	somatic	Colorectal cancer	9256	Cetuximab, Panitumumab	56842117, NA	Predictive	Supports	Resistance or Non-Response	The presence of mutation in exon 9 (such as E545K) or exon 20 may increase resistance to drugs such as  panitumumab or cetuximab.	D	19223544	3	1	
PIK3CA	5290	H1047R	somatic	Colorectal cancer	9256	Cetuximab, Panitumumab	56842117, NA	Predictive	Supports	Resistance or Non-Response	The presence of mutation in exon 9 or exon 20 (such as H1047R) may increase resistance to drugs such as  panitumumab or cetuximab.	D	19223544	3	1	
PIK3CA	5290	Exon 20	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA	B	20619739	3	1	
PIK3CA	5290	Exon 9	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Does Not Support	N/A	In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA	B	20619739	3	1	
PIK3CA	5290	H1047R	somatic	Breast cancer	1612	Rapamycin	5284616	Predictive	Supports	Sensitivity	Rapamycin inhibits transformation induced by mutation in PIK3CA	C	15647370	3	1	
PIK3CA	5290	E542K	somatic	Breast cancer	1612	Rapamycin	5284616	Predictive	Supports	Sensitivity	Rapamycin inhibits transformation induced by mutation in PIK3CA	C	15647370	3	1	
PIK3CA	5290	E545K	somatic	Breast cancer	1612	Rapamycin	5284616	Predictive	Supports	Sensitivity	Rapamycin inhibits transformation induced by mutation in PIK3CA	C	15647370	3	1	
PIK3CA	5290	E542K	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	The presence of exon 9 (such as E542K) or exon 20 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	D	19223544	3	1	
PIK3CA	5290	E545K	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	The presence of exon 9 (such as E545K) or exon 20 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	D	19223544	3	1	
PIK3CA	5290	H1047R	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	The presence of exon 20 (such as H1047R) or exon 9 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	D	19223544	3	1	
PIK3CA	5290	E542K	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.	D	22357840	2	1	
PIK3CA	5290	E545K	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival.	D	22357840	2	1	
PIK3CA	5290	E542K	somatic	Ovarian cancer	2394	N/A	N/A	Diagnostic	Supports	Positive	Patients with PIK3CA E542K/E545K mutation status are more likely to also harbor BRAF, KRAS or NRAS mutation.	D	21829508	2	0	
PIK3CA	5290	E545K	somatic	Ovarian cancer	2394	N/A	N/A	Diagnostic	Supports	Positive	Patients with PIK3CA E542K/E545K mutation status are more likely to also harbor BRAF, KRAS or NRAS mutation.	D	21829508	2	0	
PIK3CA	5290	H1047R	somatic	Ovarian cancer	2394	N/A	N/A	Diagnostic	Supports	Positive	Patients with PIK3CA H1047R mutation status are more likely to also harbor BRAF, KRAS or NRAS mutation.	D	21829508	2	0	
PDGFRA	5156	D842I	somatic	GIST	9253	Crenolanib 	10366136	Predictive	Supports	Sensitivity	In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib showed relatively high potency.	C	22745105	4	1	
PDGFRA	5156	D842V	somatic	GIST	9253	Crenolanib 	10366136	Predictive	Supports	Sensitivity	In CHO cells with PDGFRA D842V mutation resulting in imatinib resistance, crenolanib showed relatively high potency.	C	22745105	4	1	
PDGFRA	5156	D842Y	somatic	GIST	9253	Crenolanib 	10366136	Predictive	Supports	Sensitivity	In CHO cells with PDGFRA D842Y mutation resulting in imatinib resistance, crenolanib showed relatively high potency.	C	22745105	4	1	
PDGFRA	5156	del I843	somatic	GIST	9253	Crenolanib 	10366136	Predictive	Supports	Sensitivity	In CHO cells with PDGFRA deletion I843 mutation resulting in imatinib resistance, crenolanib showed relatively high potency.	C	22745105	4	1	
PDGFRA	5156	DI842-843IM	somatic	GIST	9253	Crenolanib 	10366136	Predictive	Supports	Sensitivity	In CHO cells with PDGFRA DI842-843IM mutation resulting in imatinib resistance, crenolanib showed relatively high potency.	C	22745105	4	1	
PDGFRA	5156	D842V	somatic	GIST	9253	Imatinib 	5291	Predictive	Supports	Resistance or Non-Response	While cancer with PVGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.	B	16954519	4	1	
PDGFRA	5156	D842V	somatic	GIST	9253	Imatinib 	5291	Predictive	Supports	Resistance or Non-Response	GIST cancer with D842V mutation is resistant to imatinib.	B	15928335	4	1	
PDGFRA	5156	D842V	somatic	GIST	9253	N/A	N/A	Diagnostic	Supports	Negative	GIST tumor harboring PDGFRA D842V mutation are likely to be benign	B	15146165	3	1	
PDGFRA	5156	D842V	somatic	GIST	9253	PKC412, Sirolimus 	9829523, 5284616	Predictive	Supports	Sensitivity	In patient with metastatic GIST with PDGFRA D842 mutation, the use of PKC412 combined with sirolimus has resulted in overall survival of greater than 11 weeks.	B	J Clin Oncol (Meeting Abstracts) May 2008 vol. 26 no. 15_suppl 21515, abstract only	2	0	
NRAS	4893	Q61	somatic	Melanoma	1909	Vemurafenib	42611257	Predictive	Supports	Resistance or Non-Response	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	B	23569304	4	1	
NRAS	4893	Q61	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Does Not Support	N/A	In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy.	B	20619739	3	1	
NRAS	4893	Q61	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.	B	20619739	3	1	
NRAS	4893	Exon 2	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	The presence of NRAS mutation in AML patient does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)	B	15951308	3	1	
NRAS	4893	G12	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML	B	16434492	3	1	
NRAS	4893	Exon 2	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation has poorer survival outcome and worse prognosis.	B	24666267	3	1	
NRAS	4893	Exon 3	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation has poorer survival outcome and worse prognosis.	B	24666267	3	1	
NRAS	4893	Exon 4	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation has poorer survival outcome and worse prognosis.	B	24666267	3	1	
NRAS	4893	Exon 1	somatic	Melanoma	1909	N/A	N/A	Prognostic	Supports	Poor Outcome	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS	B	22180178	3	1	
NRAS	4893	Exon 2	somatic	Melanoma	1909	N/A	N/A	Prognostic	Supports	Poor Outcome	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS	B	22180178	3	1	
NRAS	4893	Q61	somatic	Melanoma	1909	N/A	N/A	Diagnostic	Supports	Positive	Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk	B	23861977	3	1	
NRAS	4893	G13D	somatic	Melanoma	1909	17-AAG	6505803	Predictive	Supports	Sensitivity	Due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG is shown to be effective in a patient with metastatic malignant melenoma with a NRAS G13D mutation	B	18375819	2	1	
NRAS	4893	Q61L	somatic	Melanoma	1909	Temozolomide 	5394	Predictive	Supports	Sensitivity	In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months	B	21576590	2	1	
NRAS	4893	Q61R	somatic	Melanoma	1909	Temozolomide 	5394	Predictive	Supports	Sensitivity	In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months	B	21576590	2	1	
NPM1	4869	Exon 12	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	"AML with mutated NPM1" is a provisional entity in WHO classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	A	19357394	5	1	
MGMT	4255	Promoter Methylation	somatic	Glioblastoma multiforme	3068	Temozolomide	5394	Predictive	Supports	Sensitivity	In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increase survival. 	A	15758010	5	1	
MGMT	4255	Promoter Methylation	somatic	Glioblastoma multiforme	3068	O(6)-benzylguanine	4578	Predictive	Supports	Sensitivity	In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents. 	D	11070098	4	1	
MGMT	4255	Promoter Methylation	somatic	Glioblastoma multiforme	3068	Carmustine	2578	Predictive	Supports	Sensitivity	MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells. 	B	11070098	4	1	
KRAS	3845	Exon 1	somatic	Colorectal cancer	9256	Cetuximab	NA	Predictive	Supports	Resistance or Non-Response	Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab	B	16618717	4	1	
KRAS	3845	G12D	somatic	NSCLC	3908	NVP-BEZ235, ARRY-142886	11977753, 10127622	Predictive	Supports	Sensitivity	The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in lung cancer model with KRAS G12D mutation led to marked tumor regression.	C	19029981	4	1	
KRAS	3845	G13D	somatic	Colorectal	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft models	C	20978259	4	1	
KRAS	3845	G13D	somatic	Colorectal	9256	Cetuximab	56842117	Predictive	Supports	Sensitivity	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS  	B	20978259	4	1	
KRAS	3845	G13D	somatic	Colorectal	9256	Cetuximab	56842117	Predictive	Supports	Sensitivity	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft models	C	20978259	4	1	
KRAS	3845	G13D	somatic	Colorectal	9256	Cetuximab	56842117	Prognostic	Supports	Better Outcome	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS  	B	20978259	4	1	
KRAS	3845	Exon 2	somatic	Colorectal cancer	9256	Regorafenib	11167602	Predictive	Does Not Support	Sensitivity	KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment	B	24559322	4	1	
KRAS	3845	G12	somatic	Colorectal	9256	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival.	B	19934290	4	1	
KRAS	3845	Exon 2	somatic	NSCLC	3908	Gefitinib, Erlotinib	123631, 176870	Predictive	Supports	Resistance or Non-Response	In NSCLC, exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib and erlotinib	B	15696205	3	1	
KRAS	3845	G12/G13	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer	C	18202412	3	1	
KRAS	3845	G12/G13	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS	B	20619739	3	1	
KRAS	3845	G12/G13	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer	C	18202412	3	1	
KRAS	3845	G12	somatic	Leukemia	1240	N/A	N/A	Diagnostic	Supports	Positive	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation. 	B	24571676	3	1	
KRAS	3845	G13	somatic	Leukemia	1240	N/A	N/A	Diagnostic	Supports	Positive	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation. 	B	24571676	3	1	
KRAS	3845	G12D	somatic	Lung cancer	1324	N/A	N/A	Diagnostic	Supports	Positive	KRAS G12D mutation occurs in never smokers significantly more often than in smokers	B	23014527	3	1	
KRAS	3845	G12	somatic	Multiple myeloma	9538	N/A	N/A	Prognostic	Supports	Poor Outcome	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival	B	18528420	3	1	
KRAS	3845	G13	somatic	Multiple myeloma	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival	B	18528420	3	1	
KRAS	3845	G12	somatic	NSCLC	3908	N/A	N/A	Diagnostic	Does Not Support	Positive	KRAS mutations in lung patients are not associated with smoking history, age and gender	B	18794081	3	1	
KRAS	3845	G12	somatic	NSCLC	3908	N/A	N/A	Prognostic	Does Not Support	N/A	There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC	B	11208838	3	1	
KRAS	3845	G12	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC	B	15597105	3	1	
KRAS	3845	G13	somatic	NSCLC	3908	N/A	N/A	Diagnostic	Does Not Support	Negative	KRAS mutations in lung patients are not associated with smoking history, age and gender	B	18794081	3	1	
KRAS	3845	G12D	somatic	NSCLC	3908	Dabrafenib	44462760	Predictive	Supports	Resistance or Non-Response	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib. 	B	23524406	2	1	
KRAS	3845	G12	somatic	Colorectal cancer	9256	N/A	N/A	Diagnostic	Does Not Support	Negative	In colorectal cancer, BRAF and KRAS mutation are mutually exclusive	B	12941809	2	0	
KRAS	3845	G12C	somatic	Lung cancer	1324	N/A	N/A	Diagnostic	Supports	Positive	KRAS G12C occur more frequently in women than men	B	23014527	2	1	
KIT	3815	Exon 11	somatic	Melanoma	1909	Imatinib	5291	Prognostic	Supports	Better Outcome	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	B	23775962	3	1	
KIT	3815	Exon 13	somatic	Melanoma	1909	Imatinib	5291	Prognostic	Supports	Better Outcome	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	B	23775962	3	1	
KIT	3815	Exon 17	somatic	Melanoma	1909	Imatinib	5291	Prognostic	Supports	Better Outcome	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	B	23775962	3	1	
KIT	3815	Exon 11	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Prognostic	Does Not Support	N/A	KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST	B	12000708	3	1	
KIT	3815	Exon 11	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Prognostic	Does Not Support	N/A	There is no significant association between KIT mutations in exon 11, exon 9 or wild type in survival among GIST patients.	B	16551858	3	1	
KIT	3815	Exon 11	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Prognostic	Supports	Poor Outcome	KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT	B	10485475	3	1	
KIT	3815	Exon 14	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Prognostic	Supports	Poor Outcome	GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT	B	16551858	3	1	
KIT	3815	Exon 17	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Diagnostic	Supports	Positive	KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT	B	10485475	3	1	
KIT	3815	Exon 9	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Prognostic	Does Not Support	N/A	There is no significant association between KIT mutations in exon 11, exon 9 or wild type in survival among GIST patients.	B	16551858	3	1	
KIT	3815	Exon 11	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Diagnostic	Does Not Support	Negative	In GIST tumor, the mutation status of PDGFRA and KIT are mutually exclusive.	B	12522257	2	0	
KIT	3815	Exon 11	somatic	Gastric intestinal stromal tumor	9253	N/A	N/A	Diagnostic	Supports	Positive	KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT	B	10485475	2	1	
KIT	3815	Exon 11	somatic	Lung cancer	1324	N/A	N/A	Prognostic	Does Not Support	N/A	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer	B	15217946	2	1	
KIT	3815	Exon 9	somatic	Lung cancer	1324	N/A	N/A	Prognostic	Does Not Support	N/A	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer	B	15217946	2	1	
JAK2	3717	V617F	somatic	Polycythemia vera	8997	Pegylated IFN-α–2a	NA	Predictive	Supports	Sensitivity	In patients with JAK2 V617F, the use of peglated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F. 	B	16709929	4	1	
JAK2	3717	V617F	somatic	CML	8552	N/A	N/A	Diagnostic	Does Not Support	Positive	JAK2 V617F not associatted wth  lymphoid leukemia. 	B	16081687	4	1	
JAK2	3717	V617F	somatic	CML	8552	N/A	N/A	Diagnostic	Supports	Positive	JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).	B	16081687	4	1	
JAK2	3717	V617F	somatic	Lymphoid leukemia	10747	N/A	N/A	Diagnostic	Supports	Negative	JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL). 	B	16081687	4	1	
JAK2	3717	V617F	somatic	Myeloproliferative disorder	4960	N/A	N/A	Diagnostic	Supports	Positive	 rs10974944 SNP in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer	B	19287384	4	1	
JAK2	3717	V617F	somatic	Human erythroblast leukemia	1240	TG101348 	16722836	Predictive	Supports	Sensitivity	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells	C	18394554	3	1	
IDH2	3418	R140Q/L	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	The presence of IDH2 mutation such as R140Q has reduced likelihood of co-occuring with other mutation such as FLT3, NM1 or IDH1	D	21596855	3	0	
IDH2	3418	R140Q/L	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In patients with IDH2 R140Q/L mutation, the presence of mutation do not impact overall survival or disease free survival.	B	20421455	3	1	
IDH2	3418	R140Q/L	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	In AML, patients with IDH2 R140K mutation have improved overall survival compared to those with wild-type IDH2	B	21596855	3	1	
IDH2	3418	R172K	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In AML, patients with IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2	B	21596855	3	1	
IDH2	3418	R140Q/L	somatic	MDS	4972	N/A	N/A	Prognostic	Does Not Support	N/A	R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	B	22033490	3	1	
IDH2	3418	R140Q/L	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	AML patients with IDH2 mutations such as R140Q/L have event free survival and overall survival similar to those with wild-type IDH2	D	22616558	2	1	
IDH2	3418	R172K	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	The presence of IDH2 mutation such as R172K has reduced likelihood of co-occuring with other mutation such as FLT3, NM1 or IDH1	D	21596855	2	0	
IDH2	3418	R172K	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	D	22616558	2	1	
IDH2	3418	R140Q/L	somatic	MDS	4972	N/A	N/A	Prognostic	Does Not Support	N/A	In patients suffering from MDS, the presence of IDH2 mutation such as R140Q/L do not confer prognostic value (overall survival)	D	21997850	2	1	
IDH2	3418	R172K	somatic	MDS	4972	N/A	N/A	Prognostic	Does Not Support	N/A	In patients suffering from MDS, the presence of IDH2 mutation such as R172K do not confer prognostic value (overall survival)	D	21997850	2	1	
IDH2	3418	R140Q/L	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	IDH2 mutation, including R140Q/L do not co-occur with IDH1 mutation.	B	20421455	0	0	
IDH1	3417	R132	somatic	Myelodysplastic syndromes	3069	N/A	N/A	Prognostic	Supports	Poor Outcome	IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival	B	20494930	4	1	
IDH1	3417	R132	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	IDH1 expression level is significantly lower in AML patients with IDH1 R132 mutation	B	20368538	3	0	
IDH1	3417	R132C	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation	B	20538800	3	1	
IDH1	3417	R132H	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	R132 mutation often occurs with FLT3 and/or NPMc mutation in adults.	B	20376086	3	0	
IDH1	3417	R132H	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	B	20538800	3	1	
IDH1	3417	R132L	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	R132 mutation often occurs with FLT3 and/or NPMc mutation in adults.	B	20376086	3	0	
IDH1	3417	R132L	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	B	20538800	3	1	
IDH1	3417	R132	somatic	Astrocytoma	3069	N/A	N/A	Prognostic	Supports	Better Outcome	In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation.	B	19933982	3	1	
IDH1	3417	R132	somatic	Glioblastoma	3068	N/A	N/A	Prognostic	Supports	Better Outcome	In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation	B	20127344	3	1	
IDH1	3417	R132	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype.	B	20376086	2	1	
IDH1	3417	R132	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation	B	20368538	2	1	
IDH1	3417	R132C	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	IDH1 R132 mutations often occur with FLT3 and/or NPMc mutations in adults	B	20376086	2	0	
IDH1	3417	R132C	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	B	20538800	2	1	
IDH1	3417	R132G	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	R132 mutation often occurs with FLT3 and/or NPMc mutation in adults.	B	20376086	2	0	
IDH1	3417	R132H	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation	B	20538800	2	0	
IDH1	3417	R132L	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation	B	20538800	2	0	
GATA2	2624	Expression	somatic	NSCLC	3909	Bortezomib, Fasudil	387447, 3547	Predictive	Supports	Sensitivity	Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression. 	B	22624710	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In AML patients with FLT3-ITD  , concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.	B	21067377	5	1	
FLT3	2322	ITD	somatic	AML	9119	Sorafenib	216239	Predictive	Supports	Sensitivity	Sorafenib is effective in patients with FLT3 internal tandem repeat , but not in wild type or D835 mutation.	C	18230792	4	1	
FLT3	2322	TKD	somatic	AML	9119	Sorafenib	216239	Predictive	Supports	Resistance or Non-Response	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance	B	22368270	4	1	
FLT3	2322	TKD	somatic	AML	9119	Sorafenib	216239	Predictive	Supports	Resistance or Non-Response	Sorafenib is effective in patients with FLT3 internal tandem repeat , but not in wild type or D835 mutation.	C	18230792	4	1	
FLT3	2322	ITD	somatic	AML	9119	CEP701	126565	Predictive	Supports	Sensitivity	CEP701 is effective in AML patients with FLT3 mutation	B	14726387	4	1	
FLT3	2322	TKD	somatic	AML	9119	CEP701	126565	Predictive	Supports	Sensitivity	CEP701 is effective in AML patients with FLT3 mutation	B	14726387	4	1	
FLT3	2322	ITD	somatic	AML	9119	AG1296	2049	Predictive	Supports	Sensitivity	AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat	C	12357354	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Predictive	Supports	Resistance or Non-Response	FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43)	B	17957027	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD  	B	22490330	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation	B	21537333	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	B	11585760	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3	B	21537333	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation	B	21537333	4	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation	B	21537333	4	1	
FLT3	2322	TKD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In AML patients, FLT3-TKD mutation is associated with poorer disease free survival compared to patients with wild type FLT3	B	17940205	4	1	
FLT3	2322	ITD	somatic	AML	9119	SU5614	6536806	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	C	15626738	3	1	
FLT3	2322	TKD	somatic	AML	9119	SU5614	6536806	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	C	15626738	3	1	
FLT3	2322	ITD	somatic	AML	9119	ATRA	444795	Predictive	Supports	Resistance or Non-Response	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation	B	19965647	3	1	
FLT3	2322	ITD	somatic	AML	9119	Daunorubicin	30323	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	C	15626738	3	1	
FLT3	2322	TKD	somatic	AML	9119	Daunorubicin	30323	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	C	15626738	3	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type	B	11290608	3	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Predictive	Supports	Resistance or Non-Response	Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate 	B	17957027	3	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3	B	11290608	3	1	
FLT3	2322	TKD	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Positive	WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type	B	11290608	3	1	
FLT3	2322	TKD	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3	B	11290608	3	1	
FLT3	2322	TKD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed 	B	17965322	3	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate	B	17957027	2	1	
FLT3	2322	ITD	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD  	A	24801015	2	1	
ERBB2	2064	DEL 755-759	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	G309A	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	L755S	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	L755W	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	R678Q	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	V777L	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	This mutation is sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	V842I	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	5	1	
ERBB2	2064	D769H	somatic	Breast cancer	1612	Neratinib	9915743	Predictive	Supports	Sensitivity	All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.	C	23220880	4	1	
EGFR	1956	L858R	somatic	NSCLC	3908	N/A	N/A	Predictive	Supports	Sensitivity	In NSCLC patients treated with tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.	B	24457318	4	1	
EGFR	1956	T790M	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with NSCLC harboring EGFR T790M mutation has statistically worse overall survival compared to patients with L858R or other exon 19 activating mutation. 	B	24729716	4	1	
EGFR	1956	T790M	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	In NSCLC patients with T790M and another activating mutation, their progression free survival is shorter compared to those who do not possess T790M mutation.	B	24623981	4	1	
EGFR	1956	T790M	somatic	NSCLC	3908	Erlotinib, Premetrexed	176870, 394493	Predictive	Supports	Sensitivity	In a NSCLC patient with T790M and L858R mutation, combination treatment with erlotinib and premetrexed has shown to be effective.	B	24636847	3	1	
EGFR	1956	L858R	somatic	NSCLC	3908	Gefitinib, Erlotinib	123631, 176870	Predictive	Does Not Support	N/A	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib.	B	24736073	3	1	
EGFR	1956	L858R	somatic	NSCLC	3908	Gefitinib	123631	Predictive	Supports	Sensitivity	Geftinib added to pemetrexed and carboplatin showed greater effectiveness than premetrexed and carboplatin alone in treating NSCLC patients with L858R mutation.	B	24585406	3	1	
EGFR	1956	T790M	somatic	NSCLC	3908	Gefitinib	123631	Predictive	Supports	Resistance or Non-Response	In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.	B	15728811	3	1	
EGFR	1956	L858R	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Better Outcome	Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR. 	B	24662454	3	1	
EGFR	1956	T790M	somatic	NSCLC	3908	Stauroporine	44259	Predictive	Supports	Sensitivity	In NSCLC containing T790M mutation, staurosporine may be inhibitive of EGFR, especially when L858R mutation is also present.	D	24658966	1	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes	B	21067377	5	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	B	21067377	5	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In AML patients with FLT3-ITD  , concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.	B	21067377	5	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.	B	24512939	5	1	
DNMT3A	1788	R882	somatic	AML	9119	Idarubicin	42890	Predictive	Supports	Sensitivity	 Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	B	22081665	4	1	
DNMT3A	1788	R882	somatic	AML	9119	Daunorubicin	30323	Predictive	Does Not Support	NA	 Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	B	22081665	4	1	
DNMT3A	1788	Any	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	No DNMT3A mutations were identified in patients with favorable risk cytogenetics (79/215 patients)	B	21067377	4	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A mutations (59% of which were R882) were associated with IDH1, FLT3 and NPM1  	B	21067377	4	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype)	B	21067377	4	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML	B	22291079	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD  	B	22490330	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	B	22081665	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	B	22291079	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3	B	22490330	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	B	21067377	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	B	22291079	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	B	22291079	4	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A	B	22490330	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Negative	Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A R882 mutations occur most often in de novo AML patients with intermediate cytogenic risk.	B	22081665	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A R882 mutations is often associated with FLT3 internal tandem repeat in de novo AML patients.	B	22081665	3	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A R882 mutations is often associated with NPM1 mutation in de novo AML patients.	B	22081665	3	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients	B	24512939	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	In cytogenetically normal AML patients, NPM1 mutations were more common in patients with DNMT3A R882 mutations than in patients with wildtype DNMT3A	B	24512939	3	0	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	In a large cohort of cytogenetically normal AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable cytogenetically normal AMLs	B	23632886	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Young AML patients (<60 years old) with DNMT3A mutation have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A	B	22490330	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882)	B	22490330	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	Young AML patients (<60 years old) with DNMT3A R882 mutations have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A	B	22490330	3	1	
DNMT3A	1788	R882	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Poor Outcome	In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML	A	23632886	3	1	
CEBPA	1050	whole gene	somatic	AML	9119	N/A	N/A	Predictive	Does Not Support	N/A	CEBPA mutation status had no impact on ATRA treatment response in older (>60) patients with AML	B	19965647	4	1	
CEBPA	1050	whole gene	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	CEBPA mutation was significantly associated with complete remission	B	18450602	4	1	
CEBPA	1050	whole gene	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	CEBPA mutation was associated with improved overall survival in older (>60) patients with AML	B	19965647	4	1	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	CEBPA mutations were not associated with MLL-PTD in younger (16-60), cytogenetically normal AML patients 	B	14726504	3	0	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Diagnostic	Does Not Support	Negative	N-terminal loss of function CEBPA mutations were not associated with FLT3-ITD mutations in younger (16-60), cytogenetically normal AML patients	B	14726504	3	0	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Overall survival was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA mutations 	B	14726504	3	1	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Prognostic	Supports	Better Outcome	Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA  	B	14726504	3	1	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Diagnostic	Supports	Positive	CEBPA mutation was associated with higher hemoglobin levels and increased blast % in younger (16-60), cytogenetically normal AML patients	B	14726504	2	0	
CEBPA	1050	N-terminal frame shift	somatic	AML	9119	N/A	N/A	Prognostic	Does Not Support	N/A	FLT3 mutations did not alter overall survival in younger (16-60), cytogenetically normal AML patients with CEBPA  	B	14726504	2	1	
CDKN2A	1029	Promoter Hypermethylation	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence. 	B	23111194	3	1	
CDKN2A	1029	Promoter Hypermethylation	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter overall survival. 	B	23111194	3	1	
CDK6	1021	Expression	somatic	ER+ Breast cancer	60075	BYL719	5330286	Predictive	Supports	Sensitivity	In a patient-derived xenograft of a PIK3CA mutant, the combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.	B	25002028	4	1	
CDK6	1021	Expression	somatic	ER+ Breast cancer	60075	Palbociclib	5330286	Prognostic	Supports	Better Outcome	Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer. 	B	23898052	3	1	
CDK4	1019	Expression	somatic	ER+ Breast cancer	60075	BYL719	5330286	Predictive	Supports	Sensitivity	In a patient-derived xenograft of a PIK3CA mutant, the combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions.	B	25002028	4	1	
CDK4	1019	Expression	somatic	ER+ Breast cancer	60075	Palbociclib	5330286	Prognostic	Supports	Better Outcome	Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer. 	B	23898052	3	1	
CCNE1	898	Overexpression	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels. 	B	12432043	4	1	
CCNE1	898	Overexpression	somatic	Gastric sarcoma	5635	N/A	N/A	Prognostic	Supports	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma. 	B	10224221	4	1	
CCNE1	898	Overexpression	somatic	Gastric sarcoma	5635	N/A	N/A	Prognostic	Supports	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma. 	B	10224221	4	1	
CCNE1	898	Overexpression	somatic	Lung cancer	1324	N/A	N/A	Prognostic	Supports	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma. 	B	10224221	4	1	
CCND3	896	Loss	somatic	T cell leukemia	715	Palbociclib (PD-0332991)	5330286	Predictive	Supports	Sensitivity	Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival. 	C	23079656	3	1	
CCND2	894	Overexpression	somatic	Stomach cancer	10534	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers. 	C	10547574	4	1	
CCND2	894	Overexpression	somatic	Stomach cancer	10534	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	C	10547574	4	1	
CCND2	894	Overexpression	somatic	Stomach cancer	10534	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D2 overexpression is associated with poor prognosis in gastric cancers. 	C	10547574	4	1	
CCND2	894	Overexpression	somatic	Stomach cancer	10534	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers. 	C	10547574	4	1	
CCND2	894	Promoter Demethylation	somatic	Stomach cancer	10534	N/A	N/A	Diagnostic	Supports	Negative	CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II. 	C	14612939	3	1	
CCND2	894	Promoter Demethylation	somatic	Stomach cancer	10534	N/A	N/A	Predictive	Supports	Sensitivity	Treatment of CCND2-negative cells with 5-Aza-2'-deoxycytidine restored cyclin D2 expression. 	C	14612939	2	1	
BRAF	673	V600E	somatic	Melanoma	1909	Dabrafenib, Trametinib	44462760, 11707110	Predictive	Supports	Sensitivity	dabrafenib with trametinib provides higher response rate and lower toxicity-as compared to chemotherapy-in patients with melanoma.	B	24583796	5	1	
BRAF	673	V600E	somatic	Colorectal cancer	9256	N/A	N/A	Prognostic	Supports	Poor Outcome	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as poor prognosis. 	A	24594804	5	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Diagnostic	Supports	Positive	thyroid nodule with BRAF V600E mutation is highly correlated with thyroid cancer.	B	24588959	5	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Diagnostic	Supports	Positive	thyroid nodule with BRAF V600E mutation is highly correlated with thyroid cancer.	B	24570209	5	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Prognostic	Does Not Support	Poor Outcome	Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.	B	24354346	5	1	
BRAF	673	V600E amplification	somatic	Colorectal cancer	9256	AZD6244	10127622	Predictive	Supports	Resistance or Non-Response	COLO201 and COLO206F cell harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244) resistant. The mechanim of this resistence was shown to be amplification of the BRAF V600E gene.	D	21098728	4	1	
BRAF	673	V600	somatic	Melanoma	1909	N/A	N/A	Diagnostic	Supports	Positive	BRAF mutations are associated with melanoma arising in nonchronic sun damage skin and with superficial spreading melanoma	B	21166657	4	1	
BRAF	673	V600	somatic	Colorectal cancer	9256	Panitumumab	NA	Predictive	Supports	Resistance or Non-Response	In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)	B	23325582	3	1	
BRAF	673	V600E	somatic	Colorectal	9256	PD0325901, PLX4720	9826528, 24180719	Predictive	Supports	Sensitivity	Combined PD0325901 and PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation	C	23845441	3	1	
BRAF	673	V600E	somatic	Colorectal	9256	Cetuximab, Panitumumab, Sorafenib	56842117, NA, 216239	Predictive	Supports	Resistance or Non-Response	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	C	19001320	3	1	
BRAF	673	V600	somatic	Melanoma	1909	Dabrafenib, Trametinib	44462760, 11707110	Predictive	Supports	Sensitivity	Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone	B	23020132	3	1	
BRAF	673	V600E	somatic	Colorectal cancer	9256	Cetuximab	56842117	Predictive	Supports	Resistance or Non-Response	Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF	B	20619739	3	1	
BRAF	673	V600E	somatic	Melanoma	1909	N/A	N/A	Prognostic	Supports	Poor Outcome	 BRAF V600E is correlated with shorter Disease-Free and Overall Survival in a Spanish cohort of Melanoma patients. 	B	24388723	3	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Diagnostic	Supports	Positive	BRAF V600E is shown to be associated with the tall-cell variant of PTC	B	21594703	3	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Prognostic	Supports	Poor Outcome	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo). 	B	21594703	3	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Prognostic	Supports	Poor Outcome	 BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	B	24396464	3	1	
BRAF	673	V600E	somatic	Thyroid cancer	1781	N/A	N/A	Prognostic	Supports	Poor Outcome	 BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts. 	B	21594703	3	1	
BRAF	673	V600E	somatic	Melanoma	1908	N/A	N/A	Predictive	Supports	Resistance or Non-Response	BRAF V600E resistance is triggered by ERK dependent or independent pathways.	C	21505228	3	1	
BRAF	673	V600E	somatic	Melanoma	1909	Ipilimumab, Dabrafenib	NA, 44462760	Predictive	Supports	Sensitivity	treatment with immunotherapy (e.g. Ipilimumab) prior to RAF inhibitor (e.g. dabrafenib) appears to be beneficial, and better than vice versa.	B	24577748	2	1	
BRAF	673	V600E	somatic	Melanoma	1909	 Dacarbazine, Temozolomide	5281007, 5394	Predictive	Does Not Support	N/A	BRAF status does not predict prognosis in patients treated with dacarbazine or temozolomide.	B	24586605	2	1	
BRAF	673	V600E	somatic	Colorectal cancer	9256	Capecitabine, Vemurafenib, Bevacizumab	46930998, 42611257, NA	Predictive	Supports	Sensitivity	Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.	C	22180495	2	1	
BRAF	673	V600E	somatic	Colorectal	9256	PLX4720, nutlin-3	24180719, 216345	Predictive	Supports	Sensitivity	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy	C	23812671	2	1	
BRAF	673	V600E	somatic	NSCLC	3908	Dabrafenib	44462760	Predictive	Supports	Resistance or Non-Response	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib. 	B	23524406	2	1	
BRAF	673	V600E	somatic	Colorectal cancer	9256	Vemurafenib	42611257	Predictive	Supports	Sensitivity	Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation	C	22180495	2	1	
BRAF	673	V600	somatic	Colorectal cancer	9256	N/A	N/A	Diagnostic	Does Not Support	Negative	In colorectal cancer, BRAF and KRAS mutation are mutually exclusive	B	12941809	2	0	
CCND1	595	Overexpression	somatic	Breast cancer	1612	N/A	N/A	Diagnostic	Supports	Positive	Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer. 	B	15961768	4	1	
CCND1	595	Overexpression	somatic	Breast cancer	1612	N/A	N/A	Prognostic	Supports	Poor Outcome	In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.	B	15961768	4	1	
CCND1	595	Overexpression	somatic	Head and neck cancer	8618	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma. 	B	16309541	4	1	
CCND1	595	Overexpression	somatic	Mantle cell lymphoma	50746	N/A	N/A	Prognostic	Supports	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma. 	B	17891190	4	1	
CCND1	595	Amplification	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	Inceased copy number of CCND1 is associated with poorer overall survival. 	B	17070615	3	1	
CCND1	595	Expression	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	Three studies have associated CCND1 expression with poorer survival. 	B	17070615	3	1	
CCND1	595	Expression	somatic	NSCLC	3908	N/A	N/A	Prognostic	Supports	Poor Outcome	Three studies have found no significant survival impact for CCND1 in lung cancer. 	B	17070615	3	1	
ARAF	369	S214C	somatic	NSCLC	3908	Trametinib 	11707110	Predictive	Supports	Sensitivity	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells in vitro	C	24569458	3	1	
ARAF	369	S214C	somatic	NSCLC	3908	Sorafenib	216239	Predictive	Supports	Sensitivity	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells in vitro	C	24569458	3	1	
ARAF	369	S214C	somatic	NSCLC	3908	Sorafenib	216239	Predictive	Supports	Sensitivity	In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.	B	24569458	2	1	
ALK	238	F1174L	somatic	Neuroblastoma	769	TAE684	16038120	Predictive	Supports	Sensitivity	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition	C	18923525	4	1	
ALK	238	F1174L	somatic	Neuroblastoma	769	CH5424802	49806720	Predictive	Supports	Sensitivity	CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	C	21575866	3	1	
ALK	238	EML4-ALK L1196M	somatic	NSCLC	3908	CH5424802	49806720	Predictive	Supports	Sensitivity	CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation	C	21575866	3	1	
ALK	238	R1275Q	somatic	Neuroblastoma	769	TAE684	16038120	Predictive	Does Not Support	NA	TAE684 inhibits growth of Ba/F3 cells expressing ALK with the R1275Q mutation at a higher IC50 than those expressing F1174L and the SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684	C	18923525	3	1	
ALK	238	F1174L	somatic	Inflammatory myofibroblastic tumors	1115	Crizotinib	11626560	Predictive	Supports	Resistance or Non-Response	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	C	21030459	3	1	
ALK	238	F1174L	somatic	Neuroblastoma	769	Crizotinib	11626560	Predictive	Supports	Resistance or Non-Response	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	C	22072639	3	1	
ALK	238	F1174L	somatic	Neuroblastoma	769	Crizotinib	11626560	Predictive	Supports	Sensitivity	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	C	21948233	3	1	
ALK	238	R1275Q	somatic	Neuroblastoma	769	Crizotinib	11626560	Predictive	Supports	Sensitivity	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation	C	22072639	3		
ALK	238	F1174L	somatic	Inflammatory myofibroblastic tumors	1115	N/A	N/A	Diagnostic	Supports	N/A	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation showed increased capacity for growth and greater baseline ALK phosphorylation than Ba/F3 cells expressing RANBP2-ALK without this mutation.	C	21030459	3	0	
ALK	238	F1174L	somatic	NSCLC	3908	N/A	N/A	Diagnostic	Supports	N/A	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation showed increased capacity for growth and greater baseline ALK phosphorylation than Ba/F3 cells expressing EML4-ALK without this mutation.	C	21030459	3	0	
AKT1	207	E17K	somatic	Breast	1612	MK-2206	46930998	Predictive	Does Not Support	Sensitivity	PIK3CA mutation, but not AKT1 E17K, has been shown to confer sensitiity to the AKT inhibitor MK-2206 in breast cancer cell lines.	B	23888070	3	1	
ABL1	25	BCR-ABL	somatic	AML	9119	Arsenic trioxide	518740	Predictive	Supports	Sensitivity	Treatment of Philadelphia Chromosome positive leukemias with Arsenic Trioxide results in high rates of complete remission in patients. 	A	12476305	5	1	
ABL1	25	BCR-ABL	somatic	CML	8552	Imatinib	5291	Predictive	Supports	Sensitivity	The clinical use of imatinib in patients with BCR-ABL fusion has drastic sensitivity to the drug. 	A	20537386	5	1	
ABL1	25	BCR-ABL	somatic	CML	8552	Imatinib	5291	Prognostic	Supports	Better Outcome	BCR-ABL inhibitors such as imatinib have lead to "significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	A	20537386	5	1	
ABL1	25	BCR-ABL	somatic	CML	8552	Nilotinib, Dasatinib	644241, 3062316	Predictive	Supports	Sensitivity	The use of second-generation BCR-ABL targeted therapies has shown signifcantly greater response in patients resistant to imatinib. 	B	20537386	4	1	
ABL1	25	BCR-ABL	somatic	CML	8552	N/A	N/A	Diagnostic	Supports	Positive	The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease. 	A	20537386	4	1	
ABL1	25	BCR-ABL	somatic	AML	9119	Imatinib	5291	Predictive	Supports	Resistance or Non-Response	BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines. 	B	12476305	3	1	
ABL1	25	BCR-ABL	somatic	CML	8552	N/A	N/A	Diagnostic	Does Not Support	Positive	Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML. 	C	25212276	2	1	